NTRB
Price
$5.81
Change
-$0.33 (-5.37%)
Updated
Oct 22 closing price
Capitalization
70.62M
48 days until earnings call
Intraday BUY SELL Signals
VRAX
Price
$1.23
Change
-$0.11 (-8.21%)
Updated
Oct 22 closing price
Capitalization
980.3K
Intraday BUY SELL Signals
Interact to see
Advertisement

NTRB vs VRAX

NTRB vs VRAX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
NTRB vs. VRAX commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTRB is a Hold and VRAX is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for NTRB with price predictions
Oct 22, 2026

NTRB's RSI Oscillator leaves overbought zone

The 10-day RSI Indicator for NTRB moved out of overbought territory on September 25, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In 21 of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTRB as a result. In 87 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

The Moving Average Convergence Divergence Histogram (MACD) for NTRB turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 38 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.

NTRB moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

NTRB broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 50-day moving average for NTRB moved above the 200-day moving average on September 17, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +3.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRB advanced for three days, in 197 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

The Aroon Indicator entered an Uptrend today. In 77 of 113 cases where NTRB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. NTRB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.261) is normal, around the industry mean (2.973). P/E Ratio (-11.857) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (52.632) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTRB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for VRAX with price predictions
Oct 22, 2026

VRAX in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 06, 2026

VRAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 27 of 30 cases where VRAX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +7.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRAX advanced for three days, in 137 of 169 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VRAX as a result. In 70 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for VRAX turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In 33 of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for VRAX entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.185) is normal, around the industry mean (2.973). P/E Ratio (-1.008) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (79.365) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. VRAX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VRAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
NTRB: Fundamental Ratings
NTRB
OUTLOOK RATING
1..100
93
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
37
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NTRBVRAX
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
88%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 24 days ago
80%
Bullish Trend about 1 month ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
68%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (NTRB: $6.14 vs. VRAX: $1.23)
Brand notoriety: NTRB and VRAX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTRB: 16% vs. VRAX: 14%
Market capitalization -- NTRB: $70.62M vs. VRAX: $980.3K
NTRB [@Biotechnology] is valued at $70.62M. VRAX’s [@Biotechnology] market capitalization is $980.3K. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTRB’s FA Score shows that 0 FA rating(s) are green while VRAX’s FA Score has 1 green FA rating(s).

  • NTRB’s FA Score: 0 green, 5 red.
  • VRAX’s FA Score: 1 green, 4 red.
According to our system of comparison, both NTRB and VRAX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTRB’s TA Score shows that 5 TA indicator(s) are bullish while VRAX’s TA Score has 4 bullish TA indicator(s).

  • NTRB’s TA Score: 5 bullish, 5 bearish.
  • VRAX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both NTRB and VRAX are a good buy in the short-term.

Price Growth

NTRB (@Biotechnology) experienced а -2.85% price change this week, while VRAX (@Biotechnology) price change was -24.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

NTRB is expected to report earnings on Dec 09, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
NTRB
Daily Signal:
Gain/Loss:
VRAX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

NTRB and

Correlation & Price change

A.I.dvisor tells us that NTRB and VRAX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NTRB and VRAX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTRB
1D Price
Change %
NTRB100%
-5.37%
VRAX - NTRB
31%
Poorly correlated
-8.21%
DWTX - NTRB
28%
Poorly correlated
-4.27%
SYRE - NTRB
27%
Poorly correlated
-0.67%
JSPR - NTRB
27%
Poorly correlated
-1.73%
HYPD - NTRB
27%
Poorly correlated
-5.81%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PODD148.126.22
+4.38%
Insulet Corp
IPI30.77-0.43
-1.38%
Intrepid Potash
RLX1.64-0.04
-2.38%
RLX Technology
CSBR4.69-0.15
-3.10%
Champions Oncology
CISS0.52-0.02
-3.52%
C3is Inc.